Cargando…

Prognostic Roles of Blood Inflammatory Markers in Hepatocellular Carcinoma Patients Taking Sorafenib. A Systematic Review and Meta-Analysis

Objective: The purpose of this meta-analysis is to investigate the effectiveness of the prognostic roles of blood inflammatory markers in hepatocellular carcinoma (HCC) patients receiving sorafenib. Methods: We carried out a comprehensive literature search in four databases. Study endpoints, hazard...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Lixing, Gong, Yang, Zhang, Qinglin, Cai, Panpan, Feng, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000550/ https://www.ncbi.nlm.nih.gov/pubmed/32064238 http://dx.doi.org/10.3389/fonc.2019.01557

Ejemplares similares

Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram
por: Zhang, Gong, et al.
Publicado: (2022)

Prognostic Performance of Albumin–Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib
por: Zhong, Bin-Yan, et al.
Publicado: (2020)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy
por: Dong, Wei, et al.
Publicado: (2021)

Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
por: Lai, Yongting, et al.
Publicado: (2019)

Development of an Aerobic Glycolysis Index for Predicting the Sorafenib Sensitivity and Prognosis of Hepatocellular Carcinoma
por: Pan, Yu, et al.
Publicado: (2021)

The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma
por: Hu, Xinyao, et al.
Publicado: (2021)

Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
por: Zeng, Zhi, et al.
Publicado: (2021)

Corrigendum: Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
por: Lai, Yongting, et al.
Publicado: (2020)

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
por: Marisi, Giorgia, et al.
Publicado: (2018)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
por: Soria, Anna, et al.
Publicado: (2022)

Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis
por: Luo, Jia, et al.
Publicado: (2022)

The Ribosomal Protein L28 Gene Induces Sorafenib Resistance in Hepatocellular Carcinoma
por: Shi, Yi, et al.
Publicado: (2021)

Efficacy and safety of transarterial chemoembolization plus sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation
por: Zhang, Xia, et al.
Publicado: (2023)

Identification of CDCA2 as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma
por: Yu, Zhenjun, et al.
Publicado: (2021)

Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma Who have Previously Received Sorafenib
por: Rana, Nitesh, et al.
Publicado: (2013)

CISD2 Promotes Resistance to Sorafenib-Induced Ferroptosis by Regulating Autophagy in Hepatocellular Carcinoma
por: Li, Bowen, et al.
Publicado: (2021)

The current status of tumor microenvironment and cancer stem cells in sorafenib resistance of hepatocellular carcinoma
por: Chen, Siqi, et al.
Publicado: (2023)

Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
por: Liu, Jun-Ning, et al.
Publicado: (2023)

Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib
por: Zhang, Lei, et al.
Publicado: (2020)

Hepatic arterial infusion chemotherapy versus sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombus: An updated meta-analysis and systematic review
por: Zhang, Wei, et al.
Publicado: (2023)

Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
por: Liu, Jun-Ning, et al.
Publicado: (2023)

CASK Silence Overcomes Sorafenib Resistance of Hepatocellular Carcinoma Through Activating Apoptosis and Autophagic Cell Death
por: Ding, Bisha, et al.
Publicado: (2021)

Prognostic and immunological role of sulfatide-related lncRNAs in hepatocellular carcinoma
por: Huang, Xing Feng, et al.
Publicado: (2023)

Establishment of Prognostic Signatures of N6-Methyladenosine-Related lncRNAs and Their Potential Functions in Hepatocellular Carcinoma Patients
por: Wu, Xianbin, et al.
Publicado: (2022)

Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis
por: Cao, Guangchao, et al.
Publicado: (2015)

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis
por: Lencioni, R, et al.
Publicado: (2014)

Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma
por: Rizell, Magnus, et al.
Publicado: (2019)

Inhibition of Glyoxalase-I Leads to Reduced Proliferation, Migration and Colony Formation, and Enhanced Susceptibility to Sorafenib in Hepatocellular Carcinoma
por: Michel, Maurice, et al.
Publicado: (2019)

Safety and Efficacy of Transcatheter Arterial Chemoembolization Plus Radiotherapy Combined With Sorafenib in Hepatocellular Carcinoma Showing Macrovascular Invasion
por: Zhao, Yuting, et al.
Publicado: (2019)

Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis
por: Qin, Jian, et al.
Publicado: (2022)

Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma
por: Liang, Run-Bin, et al.
Publicado: (2021)

Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Treated With Transarterial Chemoembolization and Sorafenib vs. (125)Iodine Implantation
por: Hu, Hong-Tao, et al.
Publicado: (2021)

Knockdown of AKR1C3 Promoted Sorafenib Sensitivity Through Inhibiting the Phosphorylation of AKT in Hepatocellular Carcinoma
por: Zheng, Jia, et al.
Publicado: (2022)

Designer Exosomes for Targeted Delivery of a Novel Therapeutic Cargo to Enhance Sorafenib-Mediated Ferroptosis in Hepatocellular Carcinoma
por: Li, Xiaoju, et al.
Publicado: (2022)

Adjuvant Sorafenib Following Radiofrequency Ablation for Early-Stage Recurrent Hepatocellular Carcinoma With Microvascular Invasion at the Initial Hepatectomy
por: Wei, Meng-Chao, et al.
Publicado: (2022)

MAPK10 Expression as a Prognostic Marker of the Immunosuppressive Tumor Microenvironment in Human Hepatocellular Carcinoma
por: Li, Huahui, et al.
Publicado: (2021)

Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib
por: Sansone, Vito, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3kqaa9jmja9a40tqbliotiimb2